Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer

Virchows Archiv

Volumn 461, Issue 2, 2012, Pages 103-107

  Jeetle, S S ^a   Fisher, G ^a   Yang, Z H ^a   Stankiewicz, E ^a   Moller H ^b   Cooper, C S ^c   Cuzick, J ^a   Berney, D M ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Biomarker; Chromogranin; Gleason; Outcome

Indexed keywords

CHROMOGRANIN A;

ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; ENDOCRINE FUNCTION; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE DIFFERENTIATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ANDROGEN ANTAGONISTS; CELL DIFFERENTIATION; CHROMOGRANIN A; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM GRADING; NEUROENDOCRINE CELLS; PROGNOSIS; PROSTATIC NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 84867404902     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-012-1259-2     Document Type: Article

References (41)

1. Bonkhoff H, Stein U, Remberger K (1993) Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate. Virchows Arch A Pathol Anat Histopathol 423:291-294 (Pubitemid 23310596)
2. Krijnen JL, Janssen PJ, Ruizeveld de Winter JA, Van Krimpen H, Schroder FH, Van der Kwast TH (1993) Do neuroendocrine cells in human prostate cancer express androgen receptor? Histochemistry 100:393-398 (Pubitemid 23355975)
3. Ather MH, Abbas F, Faruqui N, Israr M, Pervez S (2008) Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer. BMC Urol 8:21
4. Isshiki S, Akakura K, Komiya A, Suzuki H, Kamiya N, Ito H (2002) Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol 167:512-515 (Pubitemid 34074517)
5. Di Sant'Agnese PA (1992) Neuroendocr Differ Carcinoma Prostate Cancer 70:254-268
6. Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095-2101 (Pubitemid 40617061)
7. Yokomizo A, Murai M, Baba S, Ogawa O, Tsukamoto T, Niwakawa M, Tobisu K, Kinukawa N, Naito S (2006) Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan. BJU Int 98:549-553 (Pubitemid 44185874)
8. Cuzick J, Fisher G, Kattan MW, Berney D, Oliver T, Foster CS, Moller H, Reuter V, Fearn P, Eastham J, Scardino P (2006) Longterm outcome among men with conservatively treated localised prostate cancer. Br J Cancer 95:1186-1194 (Pubitemid 44658482)
9. Tewari A, Johnson CC, Divine G, Crawford ED, Gamito EJ, Demers R, Menon M (2004) Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol 171:1513-1519 (Pubitemid 38365408)
10. Cox ME, Deeble PD, Lakhani S, Parsons SJ (1999) Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. Cancer Res 59:3821-3830 (Pubitemid 29381892)
11. Deng X, Liu H, Huang J, Cheng L, Keller ET, Parsons SJ, Hu CD (2008) Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. Cancer Res 68:9663-9670
12. Diaz M, Abdul M, Hoosein N (1998) Modulation of neuroendocrine differentiation in prostate cancer by interleukin-1 and -2. Prostate Suppl 8:32-36 (Pubitemid 28347993)
13. Huss WJ, Gregory CW, Smith GJ (2004) Neuroendocrine cell differentiation in the CWR22 human prostate cancer xenograft: association with tumor cell proliferation prior to recurrence. Prostate 60:91-97 (Pubitemid 38758574)
14. Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, Van der Kwast TH, Schroder FH, Van Steenbrugge GJ (2002) Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during longterm androgen deprivation. Prostate 50:203-215 (Pubitemid 34184659)
15. Nelson EC, Cambio AJ, Yang JC, Ok JH, Lara PN Jr, Evans CP (2007) Clinical implications of neuroendocrine differentiation in prostate cancer. Prostate Cancer Prostatic Dis 10:6-14 (Pubitemid 46358906)
16. Quiros-Gonzalez I, Sainz RM, Hevia D, Mayo JC MnSOD drives neuroendocrine differentiation, androgen independence, and cell survival in prostate cancer cells. Free Radic Biol Med 50:525-536
17. Wu C, Huang J (2007) Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer. J Biol Chem 282:3571-3583 (Pubitemid 47084471)
18. Zhang XQ, Kondrikov D, Yuan TC, Lin FF, Hansen J, Lin MF (2003) Receptor protein tyrosine phosphatase alpha signaling is involved in androgen depletion-induced neuroendocrine differentiation of androgen-sensitive LNCaP human prostate cancer cells. Oncogene 22:6704-6716 (Pubitemid 37372211)
19. Abrahamsson PA, Cockett AT, Di Sant'Agnese PA (1998) Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma. Prostate Suppl 8:37-42 (Pubitemid 28347994)
20. Krijnen JL, Bogdanowicz JF, Seldenrijk CA, Mulder PG, Van der Kwast TH (1997) The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol 158:171-174 (Pubitemid 27251617)
21. Autorino R, Di Lorenzo G, D'Armiento FP, Mignogna C, Cindolo L, De Sio M, Perdona S, De Fortuna E, Salzano L, De Placido S, D'Armiento M (2005) Neuroendocrine differentiation after neoadjuvant hormonal treatment in prostate cancer. Minerva Urol Nefrol 57:319-324 (Pubitemid 41746071)
22. Sciarra A, Mariotti G, Gentile V, Voria G, Pastore A, Monti S, Di Silverio F (2003) Neuroendocrine differentiation in human prostate tissue: is it detectable and treatable? BJU Int 91:438-445 (Pubitemid 36359624)
23. Kadmon D, Thompson TC, Lynch GR, Scardino PT (1991) Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J Urol 146:358-361
24. Gunia S, Albrecht K, Koch S, Herrmann T, Ecke T, Loy V, Linke J, Siegsmund M, May M (2008) Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability. World J Urol 26:243-250
25. Berney DM, Fisher G, Kattan MW, Oliver RT, Moller H, Fearn P, Eastham J, Scardino P, Cuzick J, Reuter VE, Foster CS (2007) Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading. BJU Int 100:1240-1244
26. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL (2005) The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29:1228-1242 (Pubitemid 41232997)
27. Turbat-Herrera EA, Herrera GA, Gore I, Lott RL, Grizzle WE, Bonnin JM (1988) Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study. Arch Pathol Lab Med 112:1100-1105 (Pubitemid 18266523)
28. Bonkhoff H (2001) Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. Ann Oncol 12(Suppl 2):S141-S144 (Pubitemid 33069704)
29. Xing N, Qian J, Bostwick D, Bergstralh E, Young CY (2001) Neuroendocrine cells in human prostate over-express the antiapoptosis protein survivin. Prostate 48:7-15
30. Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, Van der Kwast TH, Schroder FH, Van Steenbrugge GJ (2000) Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation. Cancer Res 60:741-748 (Pubitemid 30094576)
31. Allen FJ, Van Velden DJ, Heyns CF (1995) Are neuroendocrine cells of practical value as an independent prognostic parameter in prostate cancer? Br J Urol 75:751-754
32. Tan MO, Karaoglan U, Celik B, Ataoglu O, Biri H, Bozkirli I (1999) Prostate cancer and neuroendocrine differentiation. Int Urol Nephrol 31:75-82 (Pubitemid 29284491)
33. Cerovic SJ, Brajuskovic GR, Vukotic Maletic VD, Micic SR (2004) Neuroendocrine differentiation in prostate cancer. Vojnosanit Pregl 61:513-518
34. Cindolo L, Cantile M, Franco R, Chiodini P, Schiavo G, Forte I, Zlobec I, Salzano L, Botti G, Gidaro S, Terracciano L, Cillo C Parallel determination of neuroD1, chromogranin-A, KI67 and androgen receptor expression in surgically treated prostate cancers. Int Braz J Urol 37:57-66
35. Falkmer S, Askensten U, Grimelius L, Abrahamsson PA (1990) Cytochemical markers and DNA content of neuroendocrine cells in carcinoma of the prostate gland during tumour progression. Acta Histochem Suppl 38:127-132
36. Cohen RJ, Glezerson G, Haffejee Z (1991) Neuro-endocrine cells-a new prognostic parameter in prostate cancer. Br J Urol 68:258-262
37. Collado B, Gutierrez-Canas I, Rodriguez-Henche N, Prieto JC, Carmena MJ (2004) Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells. Regul Pept 119:69-75 (Pubitemid 38482104)
38. Humez S, Monet M, Legrand G, Lepage G, Delcourt P, Prevarskaya N (2006) Epidermal growth factor-induced neuroendocrine differentiation and apoptotic resistance of androgen-independent human prostate cancer cells. Endocr Relat Cancer 13:181-195
39. Di Sant'Agnese PA (2001) Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. Ann Oncol 12(Suppl 2):S135-S140 (Pubitemid 33069703)
40. Ahlgren G, Pedersen K, Lundberg S, Aus G, Hugosson J, Abrahamsson PA (2000) Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment. Prostate 42:274-279 (Pubitemid 30104570)
41. Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N (2004) Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 45:586-592, discussion 592 (Pubitemid 38481685)